Abstract: ［1］ Heider U, Kaiser M, Mieth M, et al. Serum concentrations of DKK1 decrease in patients with multiple myeloma responding to antimyeloma treatment［J］. Eur J Haematol, 2009, 82(1): 3138. ［2］ Gregory LS, Choi W, Burke L, et al. Breast cancer cells induce osteolytic bone lesions in vivo through a reduction in osteoblast activity in mice［J］. PLoS One, 2013, 8(9): e68103. ［3］ VoorzangerRousselot N, Journe F, Doriath V, et al. Assessment of circulating Dickkopf1 with a new twosite immunoassay in healthy subjects and women with breast cancer and bone metastases［J］. Calcif Tissue Int, 2009, 84(5): 348354. ［4］ D′Amelio P, Roato I, Oderda M, et al. DKK1 in prostate cancer diagnosis and follow up［J］. BMC Clin Pathol, 2014, 14(1): 11. ［5］ Larson SR, Zhang X, Dumpit R, et al. Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases［J］. Prostate, 2013, 73(9): 932940. ［6］ Rachner TD, Gbel A, BenadMehner P, et al. Dickkopf1 as a mediator and novel target in malignant bone disease［J］. Cancer Lett, 2014, 346(2): 172177. ［7］ Sato N, Yamabuki T, Takano A, et al. Wnt inhibitor Dickkopf1 as a target for passive cancer immunotherapy［J］. Cancer Res, 2010, 70(13): 53265336. ［8］ Clézardin P. Therapeutic targets for bone metastases in breast cancer［J］. Breast Cancer Res, 2011, 13(2): 207.